New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight loss drugs Mounjaro and Zepbound, in a matter of days. That’s because a federal judge has ruled that compounding pharmacies can’t keep making copies of the drug now that it’s no longer in shortage.

The increasing popularity of weight loss drugs like Wegovy, Ozempic, Mounjaro and metformin may have you wondering how all these options stack up.